$FBRX
Forte Biosciences, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020007402 Filed on February 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q3
Revenue $0.00 $10.00K $9.000K
YoY Change -100.0% 0.0% -99.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $670.0K $3.120M $3.840M
YoY Change -84.94% -10.86% -11.11%
% of Gross Profit
Research & Development $3.141M $7.600M $353.0K
YoY Change -74.74% -51.34% -97.12%
% of Gross Profit
Depreciation & Amortization $57.00K $180.0K $230.0K
YoY Change -73.61% -14.29% 15.0%
% of Gross Profit
Operating Expenses $3.141M $10.71M $17.13M
YoY Change -81.39% -43.97% 3.32%
Operating Profit -$17.12M
YoY Change -1299.93%
Interest Expense -$130.0K -$1.610M
YoY Change -56.67% 436.67%
% of Operating Profit
Other Income/Expense, Net -$23.00K $0.00 -$6.000K
YoY Change -89.2% -98.01%
Pretax Income -$2.050M -$10.58M -$18.74M
YoY Change -88.0% -45.49% -1763.85%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.050M -$10.58M -$690.0K
YoY Change 73.0% -46.01% 80.16%
Net Earnings / Revenue -105830.0% -7666.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$967.0K -$6.654M -$11.79M
COMMON SHARES
Basic Shares Outstanding 23.90M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.119M $19.77M $55.34M
YoY Change -94.86% -79.42% -30.65%
Cash & Equivalents $4.119M $6.939M $25.58M
Short-Term Investments $0.00 $12.84M $29.76M
Other Short-Term Assets $300.0K $1.100M $4.200M
YoY Change -81.25% -35.29% -19.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.51M $22.96M $59.54M
YoY Change -82.24% -76.52% -30.03%
LONG-TERM ASSETS
Property, Plant & Equipment $694.0K $1.689M $3.604M
YoY Change -81.8% -57.49% -9.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $5.000K
YoY Change -100.0% -99.6%
Total Long-Term Assets $4.123M -$15.30M $11.21M
YoY Change -68.31% -386.86% 113.33%
TOTAL ASSETS
Total Short-Term Assets $14.51M $22.96M $59.54M
Total Long-Term Assets $4.123M -$15.30M $11.21M
Total Assets $18.63M $7.658M $70.75M
YoY Change -80.33% -92.57% -21.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.627M $1.569M $2.293M
YoY Change -41.89% -53.91% -49.66%
Accrued Expenses $6.030M $343.0K $11.60M
YoY Change -46.16% -97.38% 15.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $4.700M $27.80M
YoY Change 127.27%
Total Short-Term Liabilities $12.64M $13.20M $41.75M
YoY Change -21.99% -20.14% 185.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $3.900M $81.00K $81.00K
YoY Change -59.38% -96.32% -95.95%
Total Long-Term Liabilities $3.900M $81.00K $81.00K
YoY Change -88.43% -99.69% -99.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.64M $13.20M $41.75M
Total Long-Term Liabilities $3.900M $81.00K $81.00K
Total Liabilities $16.55M $17.31M $50.95M
YoY Change -66.83% -61.47% 19.32%
SHAREHOLDERS EQUITY
Retained Earnings -$289.7M -$279.4M -$268.8M
YoY Change 24.34% 29.42%
Common Stock $291.8M $290.2M $288.6M
YoY Change 5.02% 5.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.772M -$4.769M $19.80M
YoY Change
Total Liabilities & Shareholders Equity $18.60M $28.16M $70.75M
YoY Change -80.36% -72.68% -21.74%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$2.050M -$10.58M -$690.0K
YoY Change 73.0% -46.01% 80.16%
Depreciation, Depletion And Amortization $57.00K $180.0K $230.0K
YoY Change -73.61% -14.29% 15.0%
Cash From Operating Activities -$2.865M -$10.71M -$12.69M
YoY Change -83.8% -10.3% -1450.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$170.0K
YoY Change -100.0% -72.58%
Acquisitions
YoY Change
Other Investing Activities $17.27M $19.53M
YoY Change 1304.07% -1437.67%
Cash From Investing Activities $12.72M $17.27M $19.36M
YoY Change 108.66% 2172.37% -1030.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.00K
YoY Change -95.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 45.00K -23.16M 10.00K
YoY Change -97.46% -181.21%
NET CHANGE
Cash From Operating Activities -2.865M -10.71M -12.69M
Cash From Investing Activities 12.72M 17.27M 19.36M
Cash From Financing Activities 45.00K -23.16M 10.00K
Net Change In Cash -2.820M -16.60M 6.680M
YoY Change -71.27% -195.73% -685.96%
FREE CASH FLOW
Cash From Operating Activities -$2.865M -$10.71M -$12.69M
Capital Expenditures $0.00 -$170.0K
Free Cash Flow -$10.71M -$12.52M
YoY Change -6.63% -902.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2019 dei City Area Code
CityAreaCode
858
CY2019 dei Local Phone Number
LocalPhoneNumber
412-8400
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6870000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
71082000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27997000
CY2019 us-gaap Depreciation
Depreciation
843000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2502000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23000151
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16534000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23000151
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1135000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
22956000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1689000
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001419041
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Registrant Name
EntityRegistrantName
Tocagen Inc
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity File Number
EntityFileNumber
001-38052
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1243872
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
4242 Campus Point Court
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23899261
CY2019Q2 dei Entity Public Float
EntityPublicFloat
223000000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8986000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40813000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
12835000
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
55273000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1662000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
97748000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3973000
CY2019Q4 us-gaap Liabilities
Liabilities
17312000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290215000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279400000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10848000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28160000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18036000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41000
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51080000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29113000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8556000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63515000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47256000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1699000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23630422
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2946000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-41000
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
246000
CY2018 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
935000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59238000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
208000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
679000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1260000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8911000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
81000
CY2018Q4 us-gaap Liabilities
Liabilities
44936000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
274029000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215884000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3515000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1360000
CY2019Q4 us-gaap Assets
Assets
28160000
CY2018Q4 us-gaap Assets
Assets
103081000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3218000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3404000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5242000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13094000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4744000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
36000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13204000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4027000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26201000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2201000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
58145000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103081000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16248000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45299000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12809000
CY2018 us-gaap Operating Expenses
OperatingExpenses
63889000
CY2017 us-gaap Operating Expenses
OperatingExpenses
37669000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-37628000
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1187000
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-7000
CY2019 toca Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
1439000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38928000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-124417000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
426000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
304000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4451000
CY2017 toca Conversion Of Preferred Stock To Common Stock Amount Converted
ConversionOfPreferredStockToCommonStockAmountConverted
131410000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86948000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
11057000
CY2017 toca Preferred Stock Warrants Liabilities Converted Into Warrants To Purchase Share Of Common Stock
PreferredStockWarrantsLiabilitiesConvertedIntoWarrantsToPurchaseShareOfCommonStock
89000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-34000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
594000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
479000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
252000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
299000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7575000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8060000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
33000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
8060000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
6870000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4451000
CY2018 us-gaap Depreciation
Depreciation
625000
CY2017 us-gaap Depreciation
Depreciation
292000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
1698000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
1161000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
590000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-161000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
248000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
19000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1212000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4127000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000
CY2017 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-11000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34469000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31133000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
93473000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
23155000
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3000000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
551000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
661000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68524000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43725000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
51163000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70746000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70797000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
428000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1968000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
655000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
437000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42319000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4190000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27707000
CY2018 toca Proceeds From Issuance Of Notes Payable Net Of Issuance Costs
ProceedsFromIssuanceOfNotesPayableNetOfIssuanceCosts
26325000
CY2018 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
8631000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7200000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
507000
CY2019 toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
7696000
CY2018 toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
28200000
CY2017 toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
88618000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7338000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
16000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14908000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43539000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89263000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31827000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4880000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30423000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35933000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5510000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2290000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1522000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
1210000
CY2018 toca Allowance For Tenant Improvements Included In Deferred Rent
AllowanceForTenantImprovementsIncludedInDeferredRent
1243000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
178000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000
CY2018 toca Fair Value Of Common Stock Warrants Issued In Connection With Notes Payable
FairValueOfCommonStockWarrantsIssuedInConnectionWithNotesPayable
479000
CY2017 toca Convertible Preferred Stock Converted Into Shares Of Common Stock
ConvertiblePreferredStockConvertedIntoSharesOfCommonStock
131410000
CY2017 toca Convertible Promissory Notes Principal And Accrued Interest Converted Into Shares Of Common Stock
ConvertiblePromissoryNotesPrincipalAndAccruedInterestConvertedIntoSharesOfCommonStock
11057000
CY2017 toca Deferred Equity Issuance Cost Payment Reclassified Of Equity Effective Intial Public Offering
DeferredEquityIssuanceCostPaymentReclassifiedOfEquityEffectiveIntialPublicOffering
1574000
CY2018 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
310000
CY2017 toca Deferred Equity Issuance Costs Incurred But Not Yet Paid
DeferredEquityIssuanceCostsIncurredButNotYetPaid
96000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
55273000
CY2019 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements accompanying notes. Significant estimates in the Company&#8217;s financial statements relate to clinical trial accruals, the valuation of equity awards and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Off-Balance Sheet Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash equivalents and marketable securities. The Company&#8217;s investment policy includes guidelines for the quality of the related institutions and financial instruments, and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p>
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
12825000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55296000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12835000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3288000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.65
CY2019Q4 us-gaap Restructuring Charges
RestructuringCharges
900000
CY2019 us-gaap Severance Costs1
SeveranceCosts1
200000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
21800000
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
more than 50 percent
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7304000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1599000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3331000
CY2019Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2404000
CY2018Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4535000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1116000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2840000
CY2019Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
387000
CY2018Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
3411000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
474000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
37000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
205000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
552000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1629000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6336000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6318000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2194000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
252000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
491000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
508000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
677000
CY2019 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
191972
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8060000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6870000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1698000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1699000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.061
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2018 toca Effective Income Tax Rate Reconciliation Withholding Tax
EffectiveIncomeTaxRateReconciliationWithholdingTax
-0.036
CY2019 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.014
CY2018 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.010
CY2017 toca Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-0.045
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.037
CY2019 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.188
CY2018 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.221
CY2017 toca Effective Income Tax Rate Reconciliation Net Operating Loss Carryovers Not Recognized
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryoversNotRecognized
-0.304
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.011
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.059
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.010
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.019
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.019
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.037
CY2019Q4 toca Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
32000
CY2018Q4 toca Deferred Tax Assets Deferred License Revenue
DeferredTaxAssetsDeferredLicenseRevenue
10000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3793000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3432000
CY2019Q4 toca Deferred Tax Assets Tax Debt Discount
DeferredTaxAssetsTaxDebtDiscount
79000
CY2018Q4 toca Deferred Tax Assets Tax Debt Discount
DeferredTaxAssetsTaxDebtDiscount
137000
CY2019Q4 toca Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
935000
CY2018Q4 toca Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
644000
CY2019Q4 toca Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
288000
CY2018Q4 toca Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
1134000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5127000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5357000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4386000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5107000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
741000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
250000
CY2019Q4 toca Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
739000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
741000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
250000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-700000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2600000
CY2019Q4 toca Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2019 toca Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
53800000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
34800000
CY2019Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2019Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2019 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases its office and laboratory space located in San Diego, California, under an operating lease agreement (the Lease). The Lease commenced in March 2018.
CY2019 toca Lessee Operating Lease Commenced Period
LesseeOperatingLeaseCommencedPeriod
2018-03
CY2019Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y
CY2019 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
the Company has one option to extend the Lease for a period of five additional years.
CY2019 toca Number Of Options To Extend Lease
NumberOfOptionsToExtendLease
1
CY2019 toca Lessee Operating Lease Additional Term Of Contract
LesseeOperatingLeaseAdditionalTermOfContract
P5Y
CY2019 toca Lessee Operating Lease Term Of Terminate
LesseeOperatingLeaseTermOfTerminate
P9M
CY2019 toca Lessee Operating Lease Tenant Improvement Allowance
LesseeOperatingLeaseTenantImprovementAllowance
1200000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
882000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
913000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
945000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
978000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1012000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1580000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6310000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
16880000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
16824000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
17132000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
10711000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17084000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-17114000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
12855000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15336000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
16582000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-12880000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-16089000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-383000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18735000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-10583000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
19116000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-19603000
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96

Files In Submission

Name View Source Status
0001564590-20-007402-index-headers.html Edgar Link pending
0001564590-20-007402-index.html Edgar Link pending
0001564590-20-007402.txt Edgar Link pending
0001564590-20-007402-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gbo1ligaaviy000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10k_20191231.htm Edgar Link pending
toca-20191231.xml Edgar Link completed
toca-20191231.xsd Edgar Link pending
toca-20191231_cal.xml Edgar Link unprocessable
toca-20191231_def.xml Edgar Link unprocessable
toca-20191231_lab.xml Edgar Link unprocessable
toca-20191231_pre.xml Edgar Link unprocessable
toca-ex1010_384.htm Edgar Link pending
toca-ex1011_383.htm Edgar Link pending
toca-ex1012_412.htm Edgar Link pending
toca-ex1018_540.htm Edgar Link pending
toca-ex1020_196.htm Edgar Link pending
toca-ex1021_197.htm Edgar Link pending
toca-ex231_9.htm Edgar Link pending
toca-ex311_7.htm Edgar Link pending
toca-ex312_6.htm Edgar Link pending
toca-ex321_10.htm Edgar Link pending
toca-ex42_195.htm Edgar Link pending